These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 7719325)
1. Gene expression in superficial bladder cancer in a tumor-model-system (RBT). Knopf HJ; von Moorselaar RJ; Debruyne FM; Schalken JA Investig Urol (Berl); 1994; 5():76-9. PubMed ID: 7719325 [No Abstract] [Full Text] [Related]
2. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma. Tsui KH; Cheng AJ; Chang Pe; Pan TL; Yung BY Urology; 2004 Oct; 64(4):839-44. PubMed ID: 15491744 [TBL] [Abstract][Full Text] [Related]
3. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status. Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509 [TBL] [Abstract][Full Text] [Related]
4. Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction. Christoph F; Müller M; Schostak M; Soong R; Tabiti K; Miller K Urology; 2004 Jul; 64(1):157-61. PubMed ID: 15245962 [TBL] [Abstract][Full Text] [Related]
5. p63 gene expression study and early bladder carcinogenesis. Compérat E; Bièche I; Dargère D; Ferlicot S; Laurendeau I; Benoît G; Vieillefond A; Verret C; Vidaud M; Capron F; Bedossa P; Paradis V Urology; 2007 Sep; 70(3):459-62. PubMed ID: 17905096 [TBL] [Abstract][Full Text] [Related]
6. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Zhang ZT; Pak J; Shapiro E; Sun TT; Wu XR Cancer Res; 1999 Jul; 59(14):3512-7. PubMed ID: 10416618 [TBL] [Abstract][Full Text] [Related]
7. Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. Larcher F; Robles AI; Duran H; Murillas R; Quintanilla M; Cano A; Conti CJ; Jorcano JL Cancer Res; 1996 Dec; 56(23):5391-6. PubMed ID: 8968091 [TBL] [Abstract][Full Text] [Related]
8. The role of nm23-H1 in the progression of transitional cell bladder cancer. Chow NH; Liu HS; Chan SH Clin Cancer Res; 2000 Sep; 6(9):3595-9. PubMed ID: 10999750 [TBL] [Abstract][Full Text] [Related]
9. New generation of prognostic factors in muscle invasive bladder cancer. Abi-Aad AS Acta Urol Belg; 1996 May; 64(2):47-9. PubMed ID: 8701811 [No Abstract] [Full Text] [Related]
10. Epidermal growth factor receptor-mediated autocrine and paracrine stimulation of human transitional cell carcinoma. Gleave ME; Hsieh JT; Wu HC; Hong SJ; Zhau HE; Guthrie PD; Chung LW Cancer Res; 1993 Nov; 53(21):5300-7. PubMed ID: 8221665 [TBL] [Abstract][Full Text] [Related]
11. Activation of RAS family genes in urothelial carcinoma. Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097 [TBL] [Abstract][Full Text] [Related]
12. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602 [TBL] [Abstract][Full Text] [Related]
13. Relationship between E-cadherin and fibroblast growth factor receptor 2b expression in bladder carcinomas. De Medina SG; Popov Z; Chopin DK; Southgate J; Tucker GC; Delouvée A; Thiery JP; Radvanyi F Oncogene; 1999 Oct; 18(41):5722-6. PubMed ID: 10523852 [TBL] [Abstract][Full Text] [Related]
14. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Chaffer CL; Brennan JP; Slavin JL; Blick T; Thompson EW; Williams ED Cancer Res; 2006 Dec; 66(23):11271-8. PubMed ID: 17145872 [TBL] [Abstract][Full Text] [Related]
15. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332 [TBL] [Abstract][Full Text] [Related]
16. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101 [TBL] [Abstract][Full Text] [Related]
17. Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Izawa JI; Slaton JW; Kedar D; Karashima T; Perrotte P; Czerniak B; Grossman HB; Dinney CP Oncol Rep; 2001; 8(1):9-15. PubMed ID: 11115562 [TBL] [Abstract][Full Text] [Related]
18. Molecular genetics and biochemical mechanisms in bladder cancer. Oncogenes, tumor suppressor genes, and growth factors. Sidransky D; Messing E Urol Clin North Am; 1992 Nov; 19(4):629-39. PubMed ID: 1441021 [TBL] [Abstract][Full Text] [Related]
19. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements. Kunze E; Von Bonin F; Werner C; Wendt M; Schlott T Int J Mol Med; 2006 Jan; 17(1):3-13. PubMed ID: 16328005 [TBL] [Abstract][Full Text] [Related]
20. Micro-array analysis of the effect of post-transurethral bladder tumor resection urine on transforming growth factor-beta1 dependent gene expression in transitional cell carcinoma. Zhang G; Cao Y; Xu Y; See WA Urol Oncol; 2005; 23(6):413-8. PubMed ID: 16301119 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]